Prostate Cancer Care: Advances in Risk Stratification, Imaging and Treatment

• by

• September 29, 2026

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

• by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

• September 26, 2026

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

• by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

• September 26, 2026

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer

• September 24, 2026

• 3 min